ClinicalTrials.gg
CompletedNCT00121836Updated Apr 27, 2011Results posted

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

A Phase 4 interventional study of Capecitabine and Bevacizumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 57 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-27.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
85th of 227
109 · median 54
Started
2005
with 12 others
Phase 4
6 of 233
1 open now
Registered
28th of 233
by date
Lead sponsor
12 of 233
Hoffmann-La Roche

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 85th largest by enrollment of the 227 interventional ones that give a count, is one of 13 that started in 2005, is one of 6 in phase 4, and was the 28th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer. Patients received Xeloda 1000 mg/m² orally (PO) twice daily (BID) on Days 1-15, and Avastin 15 mg intravenously (IV) on Day 1 of each 3-week cycle. The anticipated time on study treatment was until disease progression or unacceptable toxicity. The target sample size was \<100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women >=18 years of age
  • -negative breast cancer
  • Previous chemotherapy or hormonal treatment
  • >=1 measurable target lesion

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or cancer
  • Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy
  • Central nervous system metastases
  • Other within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix
  • Serious concurrent infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    1

    Drug: Capecitabine · Drug: Bevacizumab

Interventions

  • 1000 mg/m² PO BID on Days 1-15 of each 3-week cycle

    Also known as: Xeloda

  • 15 mg IV on Day 1 of each 3-week cycle

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time from date of first treatment dose (Day 1) to date of death, across the study phases regardless of the cause of death

    Time frame: approximately 505 days (Median Time to Death)

Secondary outcomes

  1. Number of Subjects With Adverse Events

    The secondary outcome measure was to evaluate the safety profile, including a summary of adverse events (AEs) assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Intensity of AEs were graded according to NCI CTCAE version 3.0 on a 5-point scale: Grade 1=Mild Discomfort, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life Threatening/Disabling and Grade 5=Death. An SAE was defined as any experience that suggested a significant hazard,contraindication, side effect, or precaution.

    Time frame: Throughout study

  2. Premature Withdrawal From Study Due to Adverse Events

    The secondary outcome measure was to evaluate the safety profile, including a summary of premature withdrawals due to adverse events occurring in more than 1 patient in either study group, by system organ class.

    Time frame: Throughout study

  3. Number of Participants With Marked Laboratory Abnormalities

    The secondary outcome measure was to evaluate the safety profile, including a summary of marked laboratory abnormalities in \>= 5% of patients. n=number of participants with the laboratory measure,Number=number of participants with the abnormality. Laboratory values were flagged as Low(L) or High(H) if they were below the lower limit or above the upper limit of Roche standard reference range, respectively. Marked laboratory abnormalities (flagged as HH and LL) were defined as those values that were outside the Roche marked reference range and showed a clinically relevant change from baseline.

    Time frame: until progressive disease or for up to 3 years

07

Results

Posted Mar 4, 2011
Limitations and caveats
The primary endpoint TTP was changed to overall survival (OS) due to issues regarding tumor assessment data based on RECIST and poor response from investigators to related queries that developed after the planned interim analysis.

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev
Started109
Completed54
Not completed55

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the time from date of first treatment dose (Day 1) to date of death, across the study phases regardless of the cause of death

Time frame:
approximately 505 days (Median Time to Death)
Reported as:
Median · Days
Overall Survival
DaysCapecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev
Overall Survival505 (420 to 672)
SecondaryNumber of Subjects With Adverse Events

The secondary outcome measure was to evaluate the safety profile, including a summary of adverse events (AEs) assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Intensity of AEs were graded according to NCI CTCAE version 3.0 on a 5-point scale: Grade 1=Mild Discomfort, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life Threatening/Disabling and Grade 5=Death. An SAE was defined as any experience that suggested a significant hazard,contraindication, side effect, or precaution.

Time frame:
Throughout study
Reported as:
Number · Participants
Number of Subjects With Adverse Events
ParticipantsCapecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +BevFirst Study Treatment Phase Only
At least 1 adverse event (AE)10854
At least 1 treatment-related AE10451
At least 1 Grade 3 or 4 AE8241
At least 1 serious adverse event (SAE)3922
At least 1 AE causing withdrawal3725
SecondaryPremature Withdrawal From Study Due to Adverse Events

The secondary outcome measure was to evaluate the safety profile, including a summary of premature withdrawals due to adverse events occurring in more than 1 patient in either study group, by system organ class.

Time frame:
Throughout study
Reported as:
Number · Participants
Premature Withdrawal From Study Due to Adverse Events
ParticipantsCapecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +BevFirst Study Treatment Phase Only
All system organ classes2537
General disorders, administration site conditions47
Musculoskeletal and connective tissue disorders26
Respiratory, thoracic and mediastinal disorders25
Renal and urinary disorders22
SecondaryNumber of Participants With Marked Laboratory Abnormalities

The secondary outcome measure was to evaluate the safety profile, including a summary of marked laboratory abnormalities in \>= 5% of patients. n=number of participants with the laboratory measure,Number=number of participants with the abnormality. Laboratory values were flagged as Low(L) or High(H) if they were below the lower limit or above the upper limit of Roche standard reference range, respectively. Marked laboratory abnormalities (flagged as HH and LL) were defined as those values that were outside the Roche marked reference range and showed a clinically relevant change from baseline.

Time frame:
until progressive disease or for up to 3 years
Reported as:
Number · Participants
Number of Participants With Marked Laboratory Abnormalities
ParticipantsCapecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev
Hematocrit (fraction) (n=104); Abnormality: Low16
Hemoglobin (g/L) (n=104); Abnormality: Low18
Platelets (10^9/L) (n=104); Abnormality: Low9
Red blood cells (10¹²/L) (n=104); Abnormality: Low15
White blood cells (10^9/L)(n=104); Abnormality:Low23
Neutrophils (10^9/L) (n=92); Abnormality: High14
Neutrophils (10^9/L) (n=92); Abnormality: Low25
Prothrombin time (ratio) (n=36); Abnormality: High3
Aspartate transaminase(U/L)(n=104)Abnormality:High19
Alanine transaminase(U/L)(n=104);Abnormality: High10
Alkaline phosphatase(U/L)(n=104);Abnormality: High11
Direct bilirubin (umol/L) (n=78);Abnormality: High4
Albumin (g/L) (n=104); Abnormality: Low13
Total protein (g/L) (n=104); Abnormality: Low8
Chloride (mmol/L) (n=104); Abnormality: Low5
Calcium (mmol/L) (n=104); Abnormality: Low10
Uric acid (umol/L) (n=94); Abnormality: High5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev—39/109 (35.8%)103/109 (94.5%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventCapecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev
PainGeneral disorders6/109
DehydrationMetabolism and nutrition disorders5/109
Chest PainGeneral disorders3/109
NauseaGastrointestinal disorders3/109
VomitingGastrointestinal disorders3/109
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders3/109
Mucosal InflammationGeneral disorders2/109
Musculoskeletal PainMusculoskeletal and connective tissue disorders2/109
FatigueGeneral disorders1/109
Influenza Like IllnessGeneral disorders1/109
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCapecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders71/109
FatigueGeneral disorders68/109
DiarrhoeaGastrointestinal disorders66/109
NauseaGastrointestinal disorders66/109
ConstipationGastrointestinal disorders41/109
VomitingGastrointestinal disorders36/109
AnorexiaMetabolism and nutrition disorders35/109
AlopeciaSkin and subcutaneous tissue disorders32/109
CoughRespiratory, thoracic and mediastinal disorders32/109
HeadacheNervous system disorders32/109

Baseline characteristics

Age Continuous
Age Continuous(Years)Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev
Mean56.7 ± 12.03
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev
Female109
Male0
08

Study locations

57 sites
  • Birmingham, Alabama 35022, United States
  • Birmingham, Alabama 35205, United States
  • Birmingham, Alabama 35209, United States
  • Birmingham, Alabama 35211, United States
  • Birmingham, Alabama 35213, United States
  • Birmingham, Alabama 35235, United States
  • Burbank, California 91505, United States
  • Glendale, California 91204, United States
  • Glendale, California 91206, United States
  • Los Angeles, California 90057, United States
  • San Diego, California 92121, United States
  • Farmington, Connecticut 06030, United States
  • Bonita Springs, Florida 34135, United States
  • Boynton Beach, Florida 33435, United States
  • Bradenton, Florida 34209, United States
  • Cape Coral, Florida 33990, United States
  • Fort Myers, Florida 33901, United States
  • Fort Myers, Florida 33908, United States
  • Naples, Florida 34102, United States
  • Naples, Florida 34119, United States
  • Port Charlotte, Florida 33980, United States
  • Sarasota, Florida 34232, United States
  • Sarasota, Florida 34236, United States
  • Venice, Florida 34292, United States
  • Atlanta, Georgia 30341, United States
  • Augusta, Georgia 30901, United States
  • Tucker, Georgia 30084, United States
  • Chicago, Illinois 60611, United States
  • Indianapolis, Indiana 46202, United States
  • Indianapolis, Indiana 46219, United States
  • Waterloo, Iowa 50702, United States
  • Scarborough, Maine 04074, United States
  • Prince Frederick, Maryland 20678, United States
  • Lansing, Michigan 48909, United States
  • Kansas City, Missouri 64064, United States
  • Kansas City, Missouri 64111, United States
  • Kansas City, Missouri 64131, United States
  • Kansas City, Missouri 64154, United States
  • Kansas City, Missouri 66112, United States
  • Kansas City, Missouri 66210, United States
  • Lincoln, Nebraska 68510, United States
  • Omaha, Nebraska 68114, United States
  • Las Vegas, Nevada 89106, United States
  • Brick, New Jersey 08724, United States
  • Neptune, New Jersey 07754, United States
  • Red Bank, New Jersey 07701, United States
  • Rochester, New York 14642, United States
  • Hickory, North Carolina 28602, United States
  • Canton, Ohio 44718, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Beaufort, South Carolina 29902, United States
  • Charleston, South Carolina 29406, United States
  • Florence, South Carolina 29506, United States
  • Hilton Head Island, South Carolina 29926, United States
  • Sumter, South Carolina 29150, United States
  • Abingdon, Virginia 24211, United States
  • Milwaukee, Wisconsin 53215, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2005
First posted
Jul 21, 2005
Start
Jun 2005
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Mar 4, 2011
Last update
Apr 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00121836
Lead sponsor
Hoffmann-La Roche
First posted
Jul 21, 2005
Start date
Jun 2005
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Mar 4, 2011
Last update
Apr 27, 2011

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Bevacizumab

Start the discussion